Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma

European Journal of Cardio-thoracic Surgery

Volumn 39, Issue 2, 2011, Pages 180-184

  Watzka, Stefan B ^a   Setinek, Ulrike ^a   Stubenberger, Elisabeth B ^a   Tötsch, Martin ^b   Dekan, Gerhard ^c   Marcher, Markus ^a   Fleck, Tatjana ^c   Müller, Michael R ^a  

^a OTTO WAGNER HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

AKT; Chemotherapy; Immunohistochemistry; Integrin linked kinase; Mesothelioma; Surgery; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; INTEGRIN LINKED KINASE; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONSERVATIVE TREATMENT; DISEASE FREE SURVIVAL; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PHOSPHORYLATION; PLEURAL NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78751569979     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.05.007     Document Type: Article

References (25)

1. Hodgson J.T., McElvenny D.M., Darnton A.J., Price M.J., Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005, 92:587-593.
2. Sterman D.H., Kaiser L.R., Albelda S.M. Advances in the treatment of malignant pleural mesothelioma. Chest 1999, 116:504-520.
3. Edwards J.G., Abrams K.R., Leverment J.N., Spyt T.J., Waller D.A., O'Byrne K.J. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000, 55:731-735.
4. Yang H., Testa J.R., Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008, 9:147-157.
5. Yang H., Bocchetta M., Kroczynska B., Elmishad A.G., Chen Y., Liu Z., Bubici C., Mossman B.T., Pass H.I., Testa J.R., Franzoso G., Carbone M. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A 2006, 103:10397-10402.
6. Hannigan G.E., Leung-Hagesteijn C., Fitz-Gibbon L., Coppolino M.G., Radeva G., Filmus J., Bell J.C., Dedhar S. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996, 379:91-96.
7. Hannigan G., Troussard A.A., Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005, 5:51-63.
8. Legate K.R., Montanez E., Kudlacek O., Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006, 7:20-31.
9. Liu J., Costello P.C., Pham N.A., Pintillie M., Jabali M., Sanghera J., Tsao M.S., Johnston M.R. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. J Thorac Oncol 2006, 1:771-779.
10. Edwards L.A., Verreault M., Thiessen B., Dragowska W.H., Hu Y., Yeung J.H., Dedhar S., Bally M.B. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther 2006, 5:645-654.
11. Yau C.Y., Wheeler J.J., Sutton K.L., Hedley D.W. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005, 65:1497-1504.
12. Tan C., Mui A., Dedhar S. Integrin-linked kinase regulates inducible nitric oxide synthase and cyclooxygenase-2 expression in an NF-kappa B-dependent manner. J Biol Chem 2002, 277:3109-3116.
13. McDonald P.C., Fielding A.B., Dedhar S. Integrin-linked kinase - essential roles in physiology and cancer biology. J Cell Sci 2008, 121:3121-3132.
14. Takanami I. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 2005, 5:1.
15. Watzka SB, Rauscher-Potsch I, Stubenberger E, Getman V, Setinek U, Totsch M, Potschger U, Muller MR. Immunoreactivity of integrin-linked kinase in primary non-small-cell lung cancer and survival after curative resection. Eur J Cardiothorac Surg 2010, doi:10.1016/j.ejcts.2010.02.006.
16. Bravou V., Klironomos G., Papadaki E., Taraviras S., Varakis J. ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. J Pathol 2006, 208:91-99.
17. Okamura M., Yamaji S., Nagashima Y., Nishikawa M., Yoshimoto N., Kido Y., Iemoto Y., Aoki I., Ishigatsubo Y. Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol 2007, 38:1081-1091.
18. Watzka S.B., Setinek U., Huber M., Cantonati H., Lax F., Watson S., Weigel G., Muller M.R. Reactivity of integrin-linked kinase in human mesothelial cell proliferation. Interact Cardiovasc Thorac Surg 2008, 7:107-110.
19. Flores R.M., Pass H.I., Seshan V.E., Dycoco J., Zakowski M., Carbone M., Bains M.S., Rusch V.W. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008, 135:620-626. e1-3.
20. Kaplan E. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
21. Dillon R.L., White D.E., Muller W.J. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007, 26:1338-1345.
22. Hortelano S., Lopez-Fontal R., Traves P.G., Villa N., Grashoff C., Bosca L., Luque A. ILK mediates LPS-induced vascular adhesion receptor expression and subsequent leucocyte trans-endothelial migration. Cardiovasc Res 2010, 86:283-292.
23. Schramm A., Opitz I., Thies S., Seifert B., Moch H., Weder W., Soltermann A. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg 2010, 37:566-572.
24. Persad S., Troussard A.A., McPhee T.R., Mulholland D.J., Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 2001, 153:1161-1174.
25. Pass H.I., Liu Z., Wali A., Bueno R., Land S., Lott D., Siddiq F., Lonardo F., Carbone M., Draghici S. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004, 10:849-859.